The recent surge in investments into boutique pharmaceutical companies, particularly those focusing on groundbreaking therapies and complex drug development programs, has fueled what some are calling "High Investor Pharma." While the potential for revolutionary treatments and impressive returns is clear, the connected risks are also considerable. M